The Diopsys® NOVA-ERG Vision Testing System is an office-based pattern electroretinography (ERG) module – a part of the Diopsys® NOVA suite of tests. Pattern electroretinography can help doctors gain objective, functional information about the performance of the inner retinal cells of the eye, especially in the macula.
- No verbal response or “button pushing” required, providing objective results.
- Report contains quantitative information formatted to facilitate physician test interpretation and patient management.
- Documents the results of practitioner intervention for tracking patients’ response.
- The Diopsys® NOVA-ERG conforms to the standards of the International Society for Clinical Electrophysiology of Vision (ISCEV)
Concentric Stimulus Fields
Information gathered is intended to be used to aid in the diagnosis and care of diseases that affect the retina in specific topographic patterns, i.e., Age-Related Macular Degeneration (AMD), Diabetes Macular Edema (CME) and Toxic Maculopathies (e.g. Plaquenil Maculopathy). These types of diseases usually have an expected pattern of macular deterioration, affecting the central or paracentral area of the macula. The NOVA-ERG Concentric Stimulus Fields test utilizes two different degrees of stimulus presented as concentric circles with contrast reversing patterns.
Designed to provide data to aid in the diagnosis and care of diseases that affect the retina in a diffuse pattern like Chronic Open Angle Glaucoma (COAG) and Diabetic Retinopathy (DR). Since there is typically no specific topographic pattern of damage, the information collected using this protocol may help in detecting the depth of the macular dysfunction. The NOVA-ERG Contrast Sensitivity test utilizes a full-screen stimulus with two different contrast levels to give an objective, functional response of the vision system at the retina.
Designed to allow the user to manually customize the stimulus to the patient and pathology, including the pattern, pattern size, and contrast level. The NOVA-ERG is designed to provide data to the doctor to help detect cellular dysfunction that can precede evident structural defects, thereby contributing to earlier detection for more specific and timely management of diseases that impair macula and ganglion cells.
*Although the previously mentioned diseases usually have an expected clinical presentation, they may develop differently. The eye care professional must individualize the usage of the NOVA-ERG depending on his/her assessment of the clinical presentation of the disease(s), patient history and risk factors, and changes to the patients’ condition that can result in subclinical manifestations that contribute to vision loss.